On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis.
During the last decades, multicomponent chemistry has gained much attention in pharmaceutical research, especially in the context of lead finding and optimization. Here, in particular, the main advantages of multicomponent reactions (MCRs) like ease of automation and high diversity generation were utilized. In consequence of these beneficial properties, a plethora of new MCRs combined with appropriate classical reaction sequences have been published, the accessible chemical space was extended steadily. In the meantime, the desired high diversity became a challenge itself, because by now the systematic use of this huge and unmanageable space for drug discovery was limited by the lack of suitable computational tools. Therefore, this article provides an insight for the rational use of this enormous chemical space in drug discovery and generic drug synthesis. In this context, a short overview of the applied chemo informatics, necessary for the virtual screening of the biggest available chemical space, is given. Furthermore, some examples for recently developed multicomponent sequences are presented.
Priaxon AG, Gmunder Straße 37-37a, 81379, Munich, Germany. kalinski@priaxon.com
Cédric
C
Kalinski
Michael
M
Umkehrer
Lutz
L
Weber
Jürgen
J
Kolb
Christoph
C
Burdack
Günther
G
Ross
D002617:Chemical Industry / Q000379:methods*; D002625:Chemistry, Organic / Q000379:methods*; D019295:Computational Biology; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D016568:Drugs, Generic / Q000138:chemical synthesis* / Q000737:chemistry*
D016568:Drugs, Generic